{"id":1011060,"date":"2026-10-16T16:04:13","date_gmt":"2026-10-16T20:04:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\/"},"modified":"2026-10-16T16:04:13","modified_gmt":"2026-10-16T20:04:13","slug":"prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\/","title":{"rendered":"Prelude Therapeutics to Participate in the Chardan Healthcare Conference"},"content":{"rendered":"
\n

WILMINGTON, Del., Oct. 16, 2026 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated<\/a> (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Chardan Healthcare Conference taking place in New York City on October 20, 2026.<\/p>\n

On Tuesday, October 20, 2026, at 2:00 p.m. ET, Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude and Bryant Lim, Chief Financial Officer, will participate in a fireside chat.<\/p>\n

A live webcast of the fireside chat can be accessed on the Company\u2019s website under Events and Presentations<\/a>. The recording will be archived and available on the Company\u2019s website for 90 days.<\/p>\n

\n
\n About Prelude Therapeutics<\/em>
\n <\/strong>
\n
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline features highly selective KAT6A degraders and JAK2V617F mutant selective inhibitors — new approaches to clinically validated targets with transformative potential for patients. We are leveraging our expertise in targeted protein degradation to create and develop next generation degrader antibody conjugates (DACs) with novel payloads. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com.<\/p>\n

\n Investor Contact:<\/strong>\u00a0
Robert Doody
Senior Vice President, Investor Relations\u00a0
Prelude Therapeutics
484.639.7235
RDoody@preludetx.com<\/a> \u00a0
\u00a0\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WILMINGTON, Del., Oct. 16, 2026 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Chardan Healthcare Conference taking place in New York City on October 20, 2026. On Tuesday, October 20, 2026, at 2:00 p.m. ET, Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude and Bryant Lim, Chief Financial Officer, will participate in a fireside chat. A live webcast of the fireside chat can be accessed on the Company\u2019s website under Events and Presentations. The recording will be archived and available on the Company\u2019s website for 90 days. About Prelude Therapeutics Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high … <\/p>\n

Continue reading “Prelude Therapeutics to Participate in the Chardan Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1011060","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPrelude Therapeutics to Participate in the Chardan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prelude Therapeutics to Participate in the Chardan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WILMINGTON, Del., Oct. 16, 2026 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Chardan Healthcare Conference taking place in New York City on October 20, 2026. On Tuesday, October 20, 2026, at 2:00 p.m. ET, Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude and Bryant Lim, Chief Financial Officer, will participate in a fireside chat. A live webcast of the fireside chat can be accessed on the Company\u2019s website under Events and Presentations. The recording will be archived and available on the Company\u2019s website for 90 days. About Prelude Therapeutics Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high … Continue reading "Prelude Therapeutics to Participate in the Chardan Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-16T20:04:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NzM4NiM3OTAwMjU1IzIyMDIzMjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Prelude Therapeutics to Participate in the Chardan Healthcare Conference\",\"datePublished\":\"2026-10-16T20:04:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\\\/\"},\"wordCount\":217,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NzM4NiM3OTAwMjU1IzIyMDIzMjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\\\/\",\"name\":\"Prelude Therapeutics to Participate in the Chardan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NzM4NiM3OTAwMjU1IzIyMDIzMjM=\",\"datePublished\":\"2026-10-16T20:04:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NzM4NiM3OTAwMjU1IzIyMDIzMjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NzM4NiM3OTAwMjU1IzIyMDIzMjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prelude Therapeutics to Participate in the Chardan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prelude Therapeutics to Participate in the Chardan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Prelude Therapeutics to Participate in the Chardan Healthcare Conference - Market Newsdesk","og_description":"WILMINGTON, Del., Oct. 16, 2026 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Chardan Healthcare Conference taking place in New York City on October 20, 2026. On Tuesday, October 20, 2026, at 2:00 p.m. ET, Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude and Bryant Lim, Chief Financial Officer, will participate in a fireside chat. A live webcast of the fireside chat can be accessed on the Company\u2019s website under Events and Presentations. The recording will be archived and available on the Company\u2019s website for 90 days. About Prelude Therapeutics Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high … Continue reading \"Prelude Therapeutics to Participate in the Chardan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-16T20:04:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NzM4NiM3OTAwMjU1IzIyMDIzMjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Prelude Therapeutics to Participate in the Chardan Healthcare Conference","datePublished":"2026-10-16T20:04:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\/"},"wordCount":217,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NzM4NiM3OTAwMjU1IzIyMDIzMjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\/","name":"Prelude Therapeutics to Participate in the Chardan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NzM4NiM3OTAwMjU1IzIyMDIzMjM=","datePublished":"2026-10-16T20:04:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NzM4NiM3OTAwMjU1IzIyMDIzMjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NzM4NiM3OTAwMjU1IzIyMDIzMjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-to-participate-in-the-chardan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Prelude Therapeutics to Participate in the Chardan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1011060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1011060"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1011060\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1011060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1011060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1011060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}